Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

241.70CHF
9:01am GMT
Change (% chg)

CHF0.00 (+0.00%)
Prev Close
CHF241.70
Open
CHF240.60
Day's High
CHF242.10
Day's Low
CHF240.60
Volume
134,958
Avg. Vol
1,540,783
52-wk High
CHF273.00
52-wk Low
CHF226.10

Latest Key Developments (Source: Significant Developments)

Abbvie Says Phase 3 Study Of Venclexta/Venclyxto In Combination With Rituxan Meets Primary Endpoint
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Abbvie Inc ::ABBVIE ANNOUNCES PHASE 3 STUDY OF VENCLEXTA™/ VENCLYXTO™ (VENETOCLAX) IN COMBINATION WITH RITUXAN® (RITUXIMAB) MEETS ITS PRIMARY ENDPOINT.ABBVIE - IN STUDY, ADVERSE EVENTS WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF VENCLEXTA/VENCLYXTO AND RITUXAN.ABBVIE - GRADE 3-4 NEUTROPENIA WAS HIGHER IN VENCLEXTA/VENCLYXTO IN COMBINATION WITH RITUXAN ARM OF TRIAL.ABBVIE - FOR PATIENTS TAKING VENCLEXTA/VENCLYXTO WITH RITUXAN, THERE WERE 6 GRADE ≥3 TLS AES IN EACH ARM.ABBVIE - FOR PATIENTS TAKING BENDAMUSTINE WITH RITUXAN, THERE WERE 2 GRADE ≥3 TLS AES IN EACH ARM.ABBVIE - FOR VENCLEXTA/VENCLYXTO IN COMBINATION WITH RITUXAN, AES LEADING TO DEATH WERE SEEN IN 10 PATIENTS.ABBVIE - FOR BENDAMUSTINE IN COMBINATION WITH RITUXAN, AES LEADING TO DEATH WERE SEEN IN 11 PATIENTS.  Full Article

Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON'S DISEASE.IONIS PHARMA SAYS ROCHE HAS EXERCISED OPTION TO LICENSE IONIS-HTT(RX).IONIS PHARMACEUTICALS INC - ROCHE WILL NOW BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIAL ACTIVITIES FOR IONIS-HTT(RX).IONIS PHARMACEUTICALS INC - IN CONJUNCTION WITH DECISION TO LICENSE IONIS-HTT(RX), IONIS EARNED A $45 MILLION LICENSE FEE FROM ROCHE..  Full Article

FDA Grants Genentech’S Avastin Full Approval For Most Aggressive Form Of Brain Cancer
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Roche Holding AG ::FDA GRANTS GENENTECH’S AVASTIN FULL APPROVAL FOR MOST AGGRESSIVE FORM OF BRAIN CANCER.GENENTECH - CONVERSION TO FULL APPROVAL WAS BASED ON TOTALITY OF EVIDENCE OF AVASTIN IN GLIOBLASTOMA, INCLUDING DATA FROM PHASE III EORTC 26101 STUDY.  Full Article

Biothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration Agreement
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Roche Holding Ag ::BIOTHERA PHARMACEUTICALS ENTERS CANCER IMMUNOTHERAPY CLINICAL TRIAL COLLABORATION AGREEMENT.‍BIOTHERA PHARMACEUTICALS - ENTERED INTO CLINICAL TRIAL COLLABORATION AGREEMENT WITH GENENTECH INC ​.‍BIOTHERA PHARMACEUTICALS - AGREEMENT TO ASSESS SAFETY AND EFFICACY OF CO'S IMPRIME PGG IN COMBINATION WITH GENENTECH'S ATEZOLIZUMAB & BEVACIZUMAB.‍BIOTHERA PHARMACEUTICALS - GENENTECH WILL CONDUCT MULTICENTER, WHICH WILL ENROLL APPROXIMATELY 40 PATIENTS IN INITIAL PHASE OF STUDY​.BIOTHERA PHARMACEUTICALS - COLLABORATION INCLUDES TESTING EXPERIMENTAL COMBINATION IN MORPHEUS, ROCHE'S CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM​.  Full Article

Roche Holding Launches HyperCap Target Enrichment Portfolio
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Roche Holding Ag ::ROCHE HOLDING AG - ‍ANNOUNCED LAUNCH OF HYPERCAP TARGET ENRICHMENT PORTFOLIO, A STREAMLINED AND FULLY INTEGRATED NGS SAMPLE PREPARATION​.  Full Article

R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I.Says rating outlook stable -R&I.  Full Article

EMA recommends approval of Roche's drug ocrelizumab for multiple sclerosis‍​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - EU Medicines Agency: :EU MEDICINES AGENCY RECOMMENDATIONS FOR NOVEMBER 2017.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF ROCHE'S DRUG OCRELIZUMAB FOR MULTIPLE SCLEROSIS.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF AMGEN'S DRUG MVASI FOR DIFFERENT TYPES OF CANCER‍​‍​.  Full Article

AC Immune to get milestone payment for Alzheimer drug
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - AC Immune Ltd :Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's disease ‍​.Says upon the dosing of the first patient in the phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million, which is expected to be paid in the fourth quarter of 2017‍​.Says this will be the third milestone payment under the 2012 strategic collaboration and licensing agreement with Genentech.  Full Article

AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ac Immune Ltd :AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's Disease.Ac Immune - ‍upon dosing of first patient in phase 2 trial of RO7105705​, co becomes eligible to get milestone payment of CHF 14 million, expected in Q4 2017.  Full Article

FDA accepts Roche filing for Avastin in advanced ovarian cancer
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Roche Holding AG :Says FDA accepts Roche's supplemental biologics license application for Avastin as a front-line treatment for women with advanced ovarian cancer.  Full Article

Bumper crop of new drugs fails to lift big pharma R&D returns

LONDON, Dec 14 It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.